AUSTIN, Texas — Approximately 30% of patients with inflammatory bowel disease developed new or worsening extraintestinal manifestations after receiving Entyvio, according to data presented at Crohn’s & Colitis Congress extraintestinal manifestations.

The previous use of biologics and concomitant immunomodulator therapy had no significant effect on extraintestinal manifestations (EIMs) after receiving vedolizumab (Entyvio, Takeda), according to the study results.

“We wanted to investigate how a gut selective agent would affect extraintestinal manifestations in inflammatory

Full Article: https://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/online/5034e0fa-d143-4f23-bcf4-3a8d4af0a8f5/extraintestinal-manifestations-develop-worsen-after-entyvio-for-ibd